Press Release Biocartis Group NV

Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leaders - Seite 2

Maria Arcila, MD received her MD degree from the University of Pittsburgh School of Medicine and completed postgraduate training in Anatomic and Clinical Pathology at Madigan Army Medical Center, followed by subspecialty fellowships at Memorial Sloan Kettering Cancer Center (MSKCC) in Molecular Genetic Pathology and Hematopathology. She has served as Director of the Molecular Pathology Laboratory at MSKCC and is currently the Deputy Chief of the Molecular Diagnostic Service at the same institution. Dr. Arcila’s research work highlights therapeutic and prognostic molecular markers in solid tumors and hematologic malignancies and her work    focuses on the expansion, validation, and implementation of clinical tests to optimize precision medicine.

Commenting on the newly appointed Medical Advisory Board, Biocartis' CEO, Roger Moody, added: “Biocartis is committed to improving patient care through faster diagnostics and broader patient access. The Biocartis Medical Advisory Board (MAB) is one of our top priorities as we commercialize tests addressing these medical needs. These global leaders are in the forefront of addressing oncology diagnostics, treatment and medical intervention. We look forward to working with the Biocartis MAB as the voice of immediate oncology needs to improve medical care and expedited intervention.”

----- END ----

More information
Investor Relations Biocartis
e-mail        [e-mail]

About Biocartis

With its revolutionary and proprietary Idylla Platform, Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, convenient, fast and suitable for any lab. The Idylla Platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster, informed treatment decisions. Idylla's continuously expanding menu of molecular diagnostic tests address key unmet clinical needs, with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal, lung and liver cancer, as well as for sepsis. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.